Phaseline

Companies › Bluefin Biomedicine

Bluefin Biomedicine: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BFB759
Human monoclonal antibody inhibiting multiple pro-inflammatory cytokines
–Phase 2Atopic Dermatitis (AD); Hidradenitis Suppurativa (HS)Feb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07105488BFB759Phase 2Atopic Dermatitis (AD)ImmunologyFeb 2027
NCT07287644BFB759Phase 2Hidradenitis Suppurativa (HS)ImmunologyAug 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Elixiron Immunotherapeutics (Hong Kong) SinoMab BioScience Aravax VivaTech International AltruBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.